Menu
← Oncology Approval Tracker
FDA DECISION ·
Gefitinib (Iressa first generic)
gefitinib · Apotex
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
First-line treatment of metastatic NSCLC with an EGFR exon 19 deletion or exon 21 substitution mutation.
LAMPGEN ANALYSIS
Why it matters
The first generic adds an option for an established EGFR-targeted drug in its defined first-line setting.
What research teams should watch
Confirm the specific EGFR variant and the selected tablet product in the prescribing workflow.
PRIMARY RECORDS